Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Knowledge Hub

Immunizing children against pneumonia also provides protection for unvaccinated people through herd immunity

A study of the 10-strain pneumococcal conjugate vaccine in rural Kenya demonstrated herd protection. Over a 4-year period following the introduction of the vaccine for infants, coupled with a “catch-up” campaign for all children 12-59 months of age, the incidence of invasive pneumococcal disease (IPD) caused by the strains in the vaccine fell by 100% in infants less than two months of age who were too young to be vaccinated. In adults (≥ 15 years old) the incidence of IPD fell by 81% and in 5-14 year olds the incidence fell by nearly 75%. The chances of unvaccinated persons becoming ill with any strain of the disease also fell significantly – by 87% in infants under two months old, by nearly half (47%) in 5-14 year olds, and by more than one-third (37%) in adults.

Full Citation:
Hammitt, L.L., Etyang, A.O., Morpeth, S.C. et al. 2019. Effect of 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya. Lancet. 393.

Title of Article: Effect of 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya

Author(s): Hammitt, L.L., Etyang, A.O., Morpeth, S.C. et al

Publication Year: 2019

Publication Name: Lancet

Publication Volume: 393

Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/31000194/

DOI (Digital Object Identifier): 10.1016/S0140-6736(18)33005-8

Topics: Health

Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia

Countries: Kenya

WHO Regions: Africa